MEDICA DEPOT

The latest retatrutide sleep apnea findings come from Eli Lilly and Company’s Phase 3 development program, where obstructive sleep apnea (OSA) is being evaluated within a nested trial arm. Current results offer an early look at how retatrutide for sleep apnea may affect apnea-hypopnea index (AHI), body weight, and safety, but they do not yet come from a dedicated, completed O...

For professionals asking questions like “Does retatrutide lower cholesterol?”, current research offers growing data on how this investigational therapy may affect blood lipids and other cardiometabolic risk factors. Retatrutide (LY3437943), developed by Eli Lilly and Company, is a once-weekly investigational peptide that activates the GIP, GLP-1, and glucagon receptors. Phase...

Anabolic osteoporosis treatments are a class of bone-forming injectable therapies used for patients at high risk of fracture, and they sit apart from the antiresorptive drugs that make up most first-line osteoporosis care. An anabolic treatment for osteoporosis works by directly stimulating osteoblasts, the cells that lay down new bone, to increase bone mineral density and re...

Determining an appropriate Ipamorelin dosage for research involves more than selecting a fixed amount. Published studies report dose by body weight, route, schedule, and study objective, so Ipamorelin peptide dosage depends on study design rather than a universal standard.[2]

This article examines published research on Ipamorelin dosage, including concentration rang...

Because Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) that ghrelin also targets, medical professionals often ask: does Ipamorelin increase appetite? The peptide was developed to selectively stimulate pulsatile growth hormone (GH) release while minimizing several endocrine effects seen with earlier growth hormone secretagogues, and yet sharing a r...